- Home
- AEVA vs ABUS Comparison
AEVA vs ABUS Comparison
Compare AEVA & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEVA | ABUS |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 766.0M | 888.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AEVA | ABUS |
|---|---|---|
| Price | $17.02 | $4.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $26.50 | $5.00 |
| AVG Volume (30 Days) | ★ 2.6M | 1.4M |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,154,000.00 | $14,606,000.00 |
| Revenue This Year | $87.44 | $125.30 |
| Revenue Next Year | $70.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 89.90 | ★ 116.64 |
| 52 Week Low | $2.52 | $2.71 |
| 52 Week High | $38.80 | $5.10 |
Technical Indicators
Market Signals| Indicator | AEVA | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 62.84 | 58.17 |
| Support Level | $12.30 | $4.65 |
| Resistance Level | $18.43 | $5.05 |
| Average True Range (ATR) | 1.13 | 0.22 |
| MACD | 0.28 | 0.01 |
| Stochastic Oscillator | 75.04 | 69.84 |
Price Performance
Historical ComparisonAbout AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.